VIDEO: Immunotherapy has 'come of age' in breast cancer
Click Here to Manage Email Alerts
In this video, Debu Tripathy, MD, professor and chair of the department of breast medical oncology at The University of Texas MD Anderson Cancer Center and a HemOnc Today Editorial Board member, discussed immunotherapy updates presented at the 38th Annual Miami Breast Cancer Conference.
“Immunotherapy has really come of age, specifically in triple negative breast cancer, and patients whose tumors express PDL-1 now have been shown to respond to two different immune checkpoint inhibitors,” Tripathy told Healio.
He also highlighted findings from the recently presented ASCENT trial, noting the subsequent approval of sacituzumab govitecan (Trodelvy, Immunomedics) after showing improvement in disease-free and overall survival in patients.
Collapse
Read more about
Click Here to Manage Email Alerts